Recent Developments in the Medicaid Drug Rebate Program
FDA Law Blog
MAY 31, 2021
CMS views accumulator programs as a way for PBMs and insurers to siphon off the benefit of manufacturer assistance so that it does not reach the patients for whom it is intended. In addition, CMS proposes to extend the effective date of a 2016 regulation that requires AMP and Best Price to include sales to purchasers in the U.S.
Let's personalize your content